Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States.
$6.81+0.15%
报价 2026-11-06
市值
$449.5M
EV
$717.6M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -26.8%
$3.94$9.30
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07仅 EPS 线✗ 收入线✓ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.2x | -0.14 → 0.33（扭亏） | 20.7 |
| FY+32028-12 | 1.4x | -0.14 → 0.66（扭亏） | 10.3 |
毛利率 66% · TTM 收入 $325M · 基数 EPS -0.14（调整后）
分歧大
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| EOLSEvolus, Inc. | $449.5M | +0.1% | +11.5% | 65.6% | – | – | – | |
| CBLLCeriBell, Inc. | $1.03B | +2.2% | +29.3% | 88.9% | – | – | – | |
| KIDSOrthoPediatrics Corp. | $829.3M | -1.4% | +12.9% | 73.8% | – | 364.7x | 253.5x | GARP |
| SLDBSolid Biosciences Inc. | $706.6M | +6.6% | +146.7% | 0% | – | – | – | |
| KMDAKamada Ltd. | $417.1M | +5.2% | – | 42.3% | 23.3x | 10.8x | – | |
| NGNENeurogene Inc. | $400M | -1.3% | -44.4% | 0% | – | – | – | |
| AUTLAutolus Therapeutics plc | $340.7M | +1.6% | – | 15.7% | – | – | – | |
| QSIQuantum-Si incorporated | $264.6M | +13.7% | -64.3% | 34.9% | – | – | – | |
| TMCITreace Medical Concepts, Inc. | $262.1M | -3.6% | -2.7% | 79.5% | – | – | – | |
| 同行中位数 | – | – | +5.1% | 38.6% | 23.3x | 187.7x | 253.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $77.2M | $84.1M | $73.1M | $90.3M | $69M | $69.4M | $68.5M | $78.9M |
| Gross Margin | 65.6% | 68% | 64.8% | 65.7% | 66.5% | 65.3% | 68.1% | 63.8% |
| Operating Margin | -10.9% | -5.4% | -9.4% | -0.3% | -16.7% | -14.7% | -22.1% | -2.9% |
| Net Income | $-12.5M | $-8.1M | $-10.7M | $130,000 | $-15.7M | $-17.1M | $-18.9M | $-6.8M |
| Diluted EPS | -0.19 | -0.12 | -0.16 | 0 | -0.24 | -0.27 | -0.3 | -0.11 |
| Operating Cash Flow | $13.5M | $-3.6M | $-10M | $12.8M | $-14.7M | $-24.8M | $-15.6M | $4.8M |